Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): The Phase 2 SATURN Study

Date
2019
Author
Buggage, Ronald
Saroj, Namrata
Sundaram, Preethi A.
Ozyazgan, Yilmaz
Nguyen, Quan Dong
Soo, Yuhwen
Varona, Rafael V.
Corp-dit-Genti, Valerie
Cheng, Yenchieh
Heissigerova, Jarmila
Callanan, David
de Smet, Marc D.
Srivastava, Sunil K.
Karkanova, Michala
Garcia-Garcia, Olga
KADAYIFÇILAR, SİBEL
Vitti, Robert
Erickson, Kristine
Athanikar, Aditya
Chu, Karen
Metadata
Show full item record
Abstract
Purpose: To assess efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treatment of posterior segment noninfectious uveitis (NIU).
URI
http://hdl.handle.net/20.500.12627/123521
https://doi.org/10.1016/j.ophtha.2018.09.044
Collections